Why Lilly and Novo are betting on amylin to power a new wave of obesity drugs after GLP-1s
Eli Lilly and Novo Nordisk are shifting focus to amylin-based therapies for obesity treatment, following the success of GLP-1 medications. Amylin agonists like petrelintide show promise in weight reduction with lower gastrointestinal side effects. The business model for metabolic therapies is moving towards high volume at reduced net prices. Lilly currently leads in market growth, while Novo defends its position with higher-dose Wegovy and oral formulations.
Listen to Live Briefing
Real-time synthesized voice briefing Β· Live Feeds Desk
- β Eli Lilly captures the majority of market growth in obesity treatments.
- β Novo Nordisk defends its standing with higher-dose Wegovy and oral formulations.
- β Amylin agonists like petrelintide may provide weight reduction with lower gastrointestinal side effects compared to GLP-1 options.
What changed
No new developments reported, existing research and market trends corroborated.
Live updates
-
Lilly and Novo bet on amylin for next-gen obesity drugs
Eli Lilly and Novo Nordisk are shifting focus to amylin-based therapies for obesity treatment, following the success of GLP-1 medications. Amylin agonists like petrelintide show promise in weight reduction with lower gastrointestinal side effects. The business model for metabolic therapies is moving towards high volume at reduced net prices. Lilly currently leads in market growth, while Novo defends its position with higher-dose Wegovy and oral formulations.
Why it matters
The obesity treatment landscape is evolving with pharmaceutical companies exploring new therapies. GLP-1 medications have seen widespread adoption, but come with gastrointestinal side effects. Amylin-based therapies offer a potential solution with fewer side effects. The market shift towards high-volume, reduced-price treatments indicates a change in the business model for metabolic therapies.
What is confirmed
- Eli Lilly captures the majority of market growth in obesity treatments.
- Novo Nordisk defends its standing with higher-dose Wegovy and oral formulations.
- Amylin agonists like petrelintide may provide weight reduction with lower gastrointestinal side effects compared to GLP-1 options.
What to watch next
- Clinical trial results for petrelintide
- Lilly and Novo's pricing strategies for amylin-based therapies
- Regulatory decisions on amylin-based treatments
confidence 80%Sources used for this update (5)
- dictionary.cambridge.org β WHY | English meaning - Cambridge Dictionary
- www.vocabulary.com β Why - Definition, Meaning & Synonyms | Vocabulary.com
- usdictionary.com β Why: Definition, Meaning, and Examples - usdictionary.com
- dictionary.cambridge.org β WHY | definition in the Cambridge English Dictionary
- www.youtube.com β Sabrina Carpenter - Why (Official Video) - YouTube
-
Eli Lilly and Novo Nordisk Target Amylin for Obesity Drugs
Pharmaceutical developers Eli Lilly and Novo Nordisk are steering obesity treatments toward amylin-based therapies following the widespread adoption of GLP-1 medications. Early research indicates that amylin agonists such as petrelintide may provide weight reduction while lowering gastrointestinal side effects compared to standard GLP-1 options. The business model for metabolic therapies is shifting from high list prices toward high volume at reduced net prices. Eli Lilly currently captures the majority of market growth, whereas Novo Nordisk defends its standing through higher-dose Wegovy and oral formulations.
Why it matters
Industry demand for GLP-1 medicines remains high while companies pivot toward combined formulations, oral pills, and monthly injections. Novo Nordisk is advancing its CagriSema combination toward regulatory review. At the same time, medical researchers are evaluating amylin treatments to deepen weight loss or treat patients who do not respond to existing GLP-1 drugs.
What is confirmed
- Demand for GLP-1 medicines continues to compound while the business model shifts from high list prices to high volume at lower net prices.
- Eli Lilly is capturing most of the market growth.
- Novo Nordisk is defending its market position with the Wegovy pill and higher-dose Wegovy.
- Petrelintide is an amylin agonist medication that early research indicates may support weight loss with fewer gastrointestinal side effects than GLP-1 drugs.
Still unconfirmed
- Amylin therapies will completely replace standalone GLP-1 treatments across all patient demographics.
What to watch next
- Regulatory review outcomes for the CagriSema combination from Novo Nordisk.
- Further clinical trial results regarding petrelintide and other amylin-based agents.
confidence 95%Sources used for this update (5)
- www.onedayadvisor.com β GLP-1 Investing Hub 2026: Eli Lilly, Novo Nordisk, Oral Pills ...
- finance.yahoo.com β Amgen vs. Novo Nordisk: Which Healthcare Giant's Stock Is a Better Buy in 2026?
- www.medicalnewstoday.com β Weight loss: Petrelintide may have fewer GI side effects than ...
- omniatelehealth.com β Petrelintide for Weight Loss: What the 2026 Lancet Trial ...
- sugarisadrug.com β What's NextβAmylin-based Therapies β Sugar is a DRUG
-
Eli Lilly and Novo Nordisk advance amylin drugs for obesity
Eli Lilly and Novo Nordisk are targeting amylin to develop a new generation of obesity treatments aimed at the 100 billion dollar market. Pharmaceutical companies are shifting development beyond standard GLP-1 efficacy toward combined formulations, daily pills, and monthly injections. Clinical trials indicate these amylin-based agents could offer substantial weight reduction alongside improved tolerability and long-term maintenance. As Novo Nordisk moves its CagriSema combination toward potential regulatory review, developers are testing amylin therapies to deepen weight loss or assist patients unresponsive to GLP-1 drugs.
Why it matters
The obesity drug market is evolving past basic GLP-1 treatments into advanced formulations that combine mechanisms such as amylin and glucagon. This transition introduces alternative formats, including oral options and monthly injections, designed to improve body composition and lower prices. Drugmakers are pursuing these strategies to capture a major share of the expanding market.
What is confirmed
- Eli Lilly and Novo Nordisk are steering obesity drug development toward amylin targets to capture a share of a 100 billion dollar market.
- Novo Nordisk is advancing its CagriSema combination toward possible regulatory review.
Still unconfirmed
- Clinical trials suggest these amylin-based agents may deliver significant weight reduction alongside better tolerability and long-term maintenance compared to standard treatments.
What to watch next
- CagriSema FDA decision expected in late 2026
- Retatrutide FDA filing planned for Q1 2027
confidence 100%Sources used for this update (3)
- www.onedaymd.com β GLP-1 2.0: The Next Generation of Obesity Drugs - onedaymd.com
- pacifictribune.com β Amylin drugs: potential successor to GLP-1 obesity medicines
- www.clinicalnutritioncenter.com β EloraTZP: Amylin + Tirzepatide Weight Loss Results
-
Drugmakers Target Amylin to Power Next Generation of Obesity Treatments
Eli Lilly and Novo Nordisk are steering obesity drug development toward amylin targets to capture a share of a 100 billion dollar market. Industry competition is evolving past basic GLP-1 efficacy toward combined formulations and novel options like pills and monthly injections. As Novo Nordisk advances its CagriSema combination toward possible regulatory review, clinical trials suggest these amylin-based agents may deliver significant weight reduction alongside better tolerability and long-term maintenance compared to standard treatments.
Why it matters
Current weight loss treatments are dominated by GLP-1 medicines, but developers are seeking gentler mechanisms and enhanced results. At least one expert suggests amylin might have been the primary target for biopharma from the start if industry priorities had aligned differently. This shift toward combination therapies and alternative delivery methods highlights how drugmakers are racing to refine obesity therapeutics.
What is confirmed
- Novo Nordisk's CagriSema is nearing possible FDA approval.
- Experts highlight growing interest in targeting amylin for obesity treatment due to potential benefits over current therapies.
- Recent clinical trials suggest new amylin agents may offer significant weight loss with improved tolerability.
Still unconfirmed
- Amylin should have been the primary target for obesity therapeutics from the start.
What to watch next
- Regulatory decisions regarding Novo Nordisk's CagriSema approval
- Further clinical trial data on combined amylin and GLP-1 formulations from Eli Lilly and Novo Nordisk
confidence 90%Sources used for this update (3)
- www.biotech-now.co.uk β Should amylin have been obesity therapeutics' primary target ...
- patientdaily.com β Experts discuss amylin as a promising target in obesity ...
- www.timeslive.co.za β Weight-loss drugmakers race for slice of $100bn pie - TimesLIVE
-
Eli Lilly and Novo Nordisk Target Amylin for Next-Gen Obesity Drugs
Eli Lilly and Novo Nordisk are steering obesity drug development toward amylin targets, aiming to achieve weight loss around 30 percent while improving long-term weight maintenance and tolerability compared to standard GLP-1 therapies. While GLP-1 treatments currently dominate the weight loss market, industry competition is evolving past basic efficacy toward gentler mechanisms and sustained results. Eli Lilly recently highlighted these advancements through new trial presentations, while Novo Nordisk continues to advance combined amylin and GLP-1 formulations.
Why it matters
GLP-1 medicines became synonymous with weight loss over the past decade, but researchers now believe amylin could offer a gentler and potentially superior primary target. Biopharma companies are racing to combine different biological pathways to secure greater durability and higher efficacy. This strategic pivot marks a major shift in how the pharmaceutical industry addresses the global obesity market.
What is confirmed
- Eli Lilly and Novo Nordisk are driving a new wave of obesity therapeutics targeting amylin alongside GLP-1 mechanisms.
- Amylin analogues are emerging as a major focus in obesity drug development for their potential to offer a gentler mechanism and better long-term results.
Still unconfirmed
- Amylin should have been the primary target for obesity therapeutics from the start if biopharma had focused on blockbuster indications ten years ago.
What to watch next
- Further clinical trial results regarding amylin and GLP-1 combination drugs from Novo Nordisk
- Additional data presentations from Eli Lilly concerning thirty percent weight loss therapies
confidence 95%Sources used for this update (3)
- www.thebionews.net β βThe era of 30% weight lossβ dawns as Eli Lilly presents its ...
- www.biospace.com β Should amylin have been obesity therapeuticsβ primary target from the start?
- www.archyde.com β Why Amylin Is Emerging as the Next Big Target in ... - Archyde
-
Eli Lilly and Novo Nordisk Target Amylin for Obesity Drugs
Eli Lilly and Novo Nordisk are advancing amylin-targeting drugs to complement or follow GLP-1 obesity treatments, aiming to boost weight loss and offer alternatives. Novo Nordisk shares rose sharply following new weight-loss data from an injectable formulation of amycretin. Meanwhile, Eli Lilly reported midstage data for eloralintide, an investigational selective amylin agonist showing significant weight reduction in trials. Researchers believe combining different biological mechanisms could produce greater and more durable weight loss than relying on incretin-based therapies alone.
Why it matters
The obesity drug market is expanding beyond the first generation of successful GLP-1 medications toward treatments that activate additional biological pathways. Developers are pursuing combinations and new mechanisms to help patients who do not receive enough benefit from existing medicines. Eli Lilly and Novo Nordisk are heavily investing in amylin-based treatments to supercharge the next wave of therapeutic options.
What is confirmed
- Eli Lilly and Novo Nordisk are developing amylin-targeting drugs to complement or replace GLP-1 obesity medications.
- Eli Lilly reported midstage data for its amylin-targeting drug eloralintide.
- Shares in Novo Nordisk rose sharply on new weight-loss data with an injectable formulation of amycretin.
Still unconfirmed
- Combining amylin-targeting drugs with existing medications will consistently produce substantially greater weight loss across all patient demographics.
What to watch next
- Phase 3 trial progress and results for eloralintide and other amylin candidates.
- Further clinical updates on amycretin from Novo Nordisk.
confidence 95%Sources used for this update (16)
- www.glp1authority.com β GLP-1 News & Updates β Daily Summaries | GLP1Authority
- rocketnews.com β Why Lilly and Novo are betting on amylin to power a new wave ...
- www.beinghealthy.news β Why Lilly and Novo Are Betting Big on Amylin to Supercharge ...
- www.europesays.com β Lilly, Novo bet on amylin obesity drugs after GLP-1s
- rocketnews.com β Why Lilly and Novo are betting on amylin to power a new wave ...
- finance.yahoo.com β Eli Lilly Targets Amylin Pathway to Unlock Next Generation ...
- business-gurus.com β Obesity Drug Competition Is Moving Beyond GLP-1s
- glpobesitymindset.substack.com β GLP-1 by Novo Nordisk vs. Lilly
- www.lqventures.com β GLP-1 Market: Next-Generation Obesity Competition | Oct 2026
- onthepen.substack.com β Amylin: The Next Big Obesity Drug Battleground
- pharmaphorum.com β Novo Nordisk leaps on new obesity drug data | pharmaphorum
- rocketnews.com β Why Lilly and Novo are betting on amylin to power a new wave ...
-
Eli Lilly and Novo Nordisk Develop Amylin-Based Obesity Treatments
Eli Lilly and Novo Nordisk are developing amylin-targeting drugs to treat obesity and diabetes, positioning amylin as a biological lever to complement or follow GLP-1 therapies. Recent data for the amylin-based drug petrelintide shows patients can lose more than 10% of their body weight with fewer side effects than current incretin-based drugs. Separately, Lilly is advancing retatrutide, a triple agonist that has delivered substantial weight loss and A1C reduction in trials for people with obesity and type 2 diabetes.
Why it matters
The pharmaceutical industry is seeking ways to increase weight loss efficacy while reducing the side effects associated with GLP-1 receptor agonists. Amylin is an emerging target that regulates appetite and glucose. This shift represents a move toward multi-agonist therapies to improve metabolic outcomes.
What is confirmed
- Eli Lilly and Novo Nordisk are developing amylin drugs for the treatment of obesity and diabetes.
- Lilly's triple agonist retatrutide produced substantial weight loss and A1C reduction in trials for people with obesity and type 2 diabetes.
- Lilly's EloraTZP, a combination of eloralintide and tirzepatide, achieved greater weight loss and A1C reduction than tirzepatide 15 mg in adults with obesity and type 2 diabetes.
Still unconfirmed
- Weekly injections of petrelintide enable patients to lose more than 10% of their body weight with far fewer side effects than existing GLP-1 RA drugs.
- Retatrutide delivered 25% weight loss at its highest dose in a Phase 3 trial.
What to watch next
- Clinical trial results for Novo Nordisk's specific amylin-based candidates.
- Comparative efficacy data between petrelintide and current GLP-1 medications.
- Regulatory filing dates for retatrutide and EloraTZP.
confidence 90%Sources used for this update (17)
- The Guardian β βGodzillaβ of weight-loss drugs could provide other important health benefits
- Scientific American β Blockbuster retatrutide trial signals a βnew high-water markβ for weight-loss drugs
- Eli Lilly β Lilly's triple agonist, retatrutide, delivered substantial weight loss and A1C reduction, underscoring its potential promise for people with obesity and type 2 diabetes
- Eli Lilly β Lilly's EloraTZP (combination of eloralintide and tirzepatide) delivered greater weight loss and A1C reduction vs. tirzepatide 15 mg in adults with obesity and type 2 diabetes
- Reuters β Experimental Lilly combination drug tops Zepbound in weight-loss trial
- WSJ β Lillyβs Next-Gen Obesity Drug Helps People Lose Even More Weight in Study
- CNBC β Why Lilly and Novo are betting on amylin to power a new wave of obesity drugs after GLP-1s
- BioPharma Dive β 3 takeaways from a European obesity scientific meeting
- www.cnbc.com β Lilly, Novo bet on amylin obesity drugs after GLP-1s
- Medscape β Retatrutide Yields Significant Weight Loss in T2D
- Simply Wall Street β Eli Lilly (LLY) Posts Strong Late Stage Obesity And Diabetes Trial Results
- ScienceAlert β Ozempic Rival Delivers 25% Weight Loss at Highest Dose in Phase 3 Trial
Community Sentiment: How do you assess this situation?
Voice your perspective Β· Real-time aggregated sentiment from the Live Feeds community